Ptc Therapeutics (PTCT) news
Recent news
PTC to acquire BLA-stage ST-920 Fabry disease program
PTC Therapeutics has announced plans to acquire the BLA-stage gene therapy program ST-920, developed by Sangamo Therapeutics for the treatment of Fabry disease. The acquisition follows Sangamo’s recent advancement of a rolling submission of a Biologics License Application (BLA) to the U.S. Food and…
AInvest Wire · Aug 12, 2026PTC Therapeutics: Morgan Stanley raises target price to $104.00 from $93.00
Morgan Stanley has raised its price target for PTC Therapeutics (NASDAQ:PTCT) to $104.00 from $93.00, reflecting a 11.8% increase in its valuation outlook for the biopharmaceutical company. The firm maintains an Overweight rating on the stock, aligning with its positive sentiment toward PTC’s…
AInvest Wire · Jul 31, 2026PTC Therapeutics Q2 product revenue USD 238.8 million (corrects amount)
AInvest Wire · Jul 30, 2026PTCT sees FY total revenue $1.18B to $1.28B, saw $1.08B to $1.18B
AInvest Wire · Jul 30, 2026PTC Therapeutics: total product revenue guidance raised to $850 to $950 million for FY 2026
AInvest Wire · Jul 30, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.